InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... which sells contact lenses as well as ophthalmic pharmaceuticals, intraocular lenses, and eye surgery products ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

The pupillary dilation caused by phenylephrine and tropicamide can be reversed with dapiprazole hydrocloride (Rev-Eyes™, Storz Ophthalmic, a division of Bausch & Lomb, Rochester, NY) Dapiprazole ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

The key players in the global ophthalmic lasers market include Alcon, Bausch + Lomb, Johnson & Johnson, NIDEK, and ZEISS. Furthermore, Alcon, a prominent player in the global healthcare sector ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX ... founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Bausch + Lomb Corporation (NYSE/TSX ... Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA and other serious eye diseases.